The label Cicada has been attached to a newly tracked COVID variant that appears to be clustering in children. Early surveillance reports point to higher detection rates in pediatric clinics and school testing programs, while adult case numbers linked to the same lineage remain relatively limited.
Preliminary genomic sequencing suggests that Cicada carries mutations on the spike protein and in non-structural proteins involved in viral replication. These changes may alter viral affinity for receptors in the upper respiratory tract and could influence viral load dynamics, but laboratory work on viral fitness and immune escape is still underway.
Clinicians describe mostly mild upper respiratory symptoms in infected children, yet patterns of fever, cough and fatigue resemble earlier Omicron-lineage infections. Researchers are now examining neutralizing antibody titers in vaccinated and previously infected children to understand how existing immunity, including mucosal immunity, interacts with this new variant.
Public health agencies are increasing wastewater surveillance and contact-tracing around schools to map Cicada’s basic reproduction number and secondary attack rates within households. The focus is on whether child-driven spread will shift overall transmission networks or strain pediatric care capacity, even if adult disease burden stays comparatively low.
